AbbVie Loses Second Consecutive Bellwether Suit Over AndroGel Risks
A jury awarded $140 million to the plaintiff in a suit against AbbVie over its testosterone replacement drug AndroGel.
The verdict is the second one against AbbVie in a series of “bellwether” trials intended to give the plaintiffs and defendants a clearer idea of potential damages and define their legal strategies.
More than 6,000 plaintiffs have filed similar cases against the company.
Like the other plaintiffs, Jeffrey Konrad, who filed the lawsuit in 2015, claimed AbbVie misrepresented AndroGel’s risks, which contributed to him having a heart attack. The company argued the heart attack was the result of unrelated factors such as obesity and high blood pressure and denied misrepresenting the drug’s safety.